Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

NCT04479358 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

85

Enrollment

OTHER

Sponsor class

Stopped Lack of recruitment of patients into the trial

Conditions

COVID-19

Interventions

DRUG: Tocilizumab
DRUG: Tocilizumab
OTHER: Standard of Care
OTHER: Standard of Care

Sponsor

University of Chicago